caa a22 4500 445332360 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10198-010-0250-6 doi (NATIONALLICENCE)springer-10.1007/s10198-010-0250-6 Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data [Elektronische Daten] [Laurent Molinier, Christel Castelli, Eric Bauvin, Xavier Rebillard, Michel Soulié, Jean-Pierre Daurès, Pascale Grosclaude] Prostate cancer is an important disease in terms of economic implications because of its increasing incidence and health care costs. We assessed the direct costs of the clinical management of prostate cancer in France. A retrospective study based on population-based data was carried out. Eight hundred and seventy-nine cases of prostate cancer diagnosed in five departments were included in a 5-year follow-up study. The economic analysis adopted the health-care payer's perspective and took into account only the direct costs. The mean cost of managing patients was estimated at €12,731. It is composed of 49 to 82% of initial treatments according to the therapeutic strategy. The follow-up constituted between 3 and 11%, the costs of treatments for side effects between 1 and 3% and the travel cost between 3 and 7%. Cumulative total costs over 5years for each treatment group showed variation in costs. Costs were highest for patients who were treated with external-beam radiotherapy and lowest for those with watchful waiting. The cost burden of prostate cancer is high and varies according to the treatment type. This study yielded a cost analysis of the different management practices of patients with prostate cancer. Springer-Verlag, 2010 Prostate cancer nationallicence Management nationallicence Cost study nationallicence Population-based data nationallicence Molinier Laurent Faculté de Médecine, INSERM U558, Toulouse, France aut Castelli Christel Laboratoire de Biostatistique, Institut Universitaire de Recherche Clinique, Montpellier, France aut Bauvin Eric Faculté de Médecine, INSERM U558, Toulouse, France aut Rebillard Xavier Service d'urologie, Clinique Beau-Soleil, Montpellier, France aut Soulié Michel Faculté de Médecine, INSERM U558, Toulouse, France aut Daurès Jean-Pierre Laboratoire de Biostatistique, Institut Universitaire de Recherche Clinique, Montpellier, France aut Grosclaude Pascale Faculté de Médecine, INSERM U558, Toulouse, France aut The European Journal of Health Economics Springer-Verlag 12/4(2011-08-01), 363-371 1618-7598 12:4<363 2011 12 10198 https://doi.org/10.1007/s10198-010-0250-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0250-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Molinier Laurent Faculté de Médecine, INSERM U558, Toulouse, France aut NATIONALLICENCE 700 1- Castelli Christel Laboratoire de Biostatistique, Institut Universitaire de Recherche Clinique, Montpellier, France aut NATIONALLICENCE 700 1- Bauvin Eric Faculté de Médecine, INSERM U558, Toulouse, France aut NATIONALLICENCE 700 1- Rebillard Xavier Service d'urologie, Clinique Beau-Soleil, Montpellier, France aut NATIONALLICENCE 700 1- Soulié Michel Faculté de Médecine, INSERM U558, Toulouse, France aut NATIONALLICENCE 700 1- Daurès Jean-Pierre Laboratoire de Biostatistique, Institut Universitaire de Recherche Clinique, Montpellier, France aut NATIONALLICENCE 700 1- Grosclaude Pascale Faculté de Médecine, INSERM U558, Toulouse, France aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/4(2011-08-01), 363-371 1618-7598 12:4<363 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer